{"transactions":[{"id":673185,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T20:16:09.000Z","date":"2026-08-26","kind":"sale","planned":false,"acquired":false,"shares":18300,"price":2.97,"value":54351.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 655,170 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2840635,"source":{"system":"sec-edgar","filing":"0001178579-26-000018","document":"form4-08282026_080804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000018/form4-08282026_080804.xml","form_type":"4"}},{"id":705282,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-21T23:38:58.000Z","date":"2026-07-21","kind":"purchase","planned":false,"acquired":true,"shares":2975,"price":2.44,"value":7259.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 655,170 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2858935,"source":{"system":"sec-edgar","filing":"0001178579-26-000017","document":"form4-07212026_110753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000017/form4-07212026_110753.xml","form_type":"4"}},{"id":705281,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-21T23:38:58.000Z","date":"2026-07-20","kind":"purchase","planned":false,"acquired":true,"shares":1623,"price":2.44,"value":3960.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 655,170 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2855960,"source":{"system":"sec-edgar","filing":"0001178579-26-000017","document":"form4-07212026_110753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000017/form4-07212026_110753.xml","form_type":"4"}},{"id":705280,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-21T23:38:58.000Z","date":"2026-07-17","kind":"purchase","planned":false,"acquired":true,"shares":265,"price":2.44,"value":646.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 655,170 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2854337,"source":{"system":"sec-edgar","filing":"0001178579-26-000017","document":"form4-07212026_110753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000017/form4-07212026_110753.xml","form_type":"4"}},{"id":708287,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-17T00:10:50.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":18491,"price":2.44,"value":45118.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $2.43 to $2.44."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 654,055 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2854072,"source":{"system":"sec-edgar","filing":"0001178579-26-000015","document":"form4-07172026_120745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000015/form4-07172026_120745.xml","form_type":"4"}},{"id":708286,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-17T00:10:50.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":2.44,"value":3904.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were all purchased at $2.44."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 654,055 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2835581,"source":{"system":"sec-edgar","filing":"0001178579-26-000015","document":"form4-07172026_120745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000015/form4-07172026_120745.xml","form_type":"4"}},{"id":708285,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-17T00:10:50.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":43878,"price":2.43,"value":106623.54,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.41 to $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 654,055 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2833981,"source":{"system":"sec-edgar","filing":"0001178579-26-000015","document":"form4-07172026_120745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000015/form4-07172026_120745.xml","form_type":"4"}},{"id":710774,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T23:06:11.000Z","date":"2026-07-13","kind":"purchase","planned":false,"acquired":true,"shares":48211,"price":2.42,"value":116670.62,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $2.35 to $2.44."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 639,395 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2790103,"source":{"system":"sec-edgar","filing":"0001178579-26-000011","document":"form4-07132026_110705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000011/form4-07132026_110705.xml","form_type":"4"}},{"id":710773,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T23:06:11.000Z","date":"2026-07-10","kind":"purchase","planned":false,"acquired":true,"shares":43367,"price":2.43,"value":105381.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $2.38 to $2.48."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 639,395 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2741892,"source":{"system":"sec-edgar","filing":"0001178579-26-000011","document":"form4-07132026_110705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000011/form4-07132026_110705.xml","form_type":"4"}},{"id":710772,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T23:06:11.000Z","date":"2026-07-09","kind":"purchase","planned":false,"acquired":true,"shares":7,"price":2.48,"value":17.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were all purchased at $2.48. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 639,395 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2698525,"source":{"system":"sec-edgar","filing":"0001178579-26-000011","document":"form4-07132026_110705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000011/form4-07132026_110705.xml","form_type":"4"}},{"id":712971,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T00:06:07.000Z","date":"2026-07-08","kind":"purchase","planned":false,"acquired":true,"shares":14338,"price":2.46,"value":35271.48,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.48."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 618,407 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2698518,"source":{"system":"sec-edgar","filing":"0001178579-26-000010","document":"form4-07092026_120702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000010/form4-07092026_120702.xml","form_type":"4"}},{"id":712970,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T00:06:07.000Z","date":"2026-07-07","kind":"purchase","planned":false,"acquired":true,"shares":15810,"price":2.48,"value":39208.8,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 618,407 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2684180,"source":{"system":"sec-edgar","filing":"0001178579-26-000010","document":"form4-07092026_120702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000010/form4-07092026_120702.xml","form_type":"4"}},{"id":712969,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T00:06:07.000Z","date":"2026-07-06","kind":"purchase","planned":false,"acquired":true,"shares":27062,"price":2.49,"value":67384.38,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 618,407 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2668370,"source":{"system":"sec-edgar","filing":"0001178579-26-000010","document":"form4-07092026_120702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000010/form4-07092026_120702.xml","form_type":"4"}},{"id":714858,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714857,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":2.49,"value":39840.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714856,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":1.03,"value":16480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":715213,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32121,"kind":"organization","name":"ARCH Venture Fund IX, L.P.","position":1,"cik":"0001666306","reported_name":"ARCH Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32122,"kind":"organization","name":"ARCH Venture Fund IX Overage, L.P.","position":2,"cik":"0001666307","reported_name":"ARCH Venture Fund IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":3,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32124,"kind":"organization","name":"ARCH Venture Partners IX, L.P.","position":4,"cik":"0001723173","reported_name":"ARCH Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32125,"kind":"organization","name":"ARCH Venture Partners IX Overage, L.P.","position":5,"cik":"0001723172","reported_name":"ARCH Venture Partners IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":6,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32127,"kind":"organization","name":"ARCH Venture Partners IX, LLC","position":7,"cik":"0001723174","reported_name":"ARCH Venture Partners IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":8,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-06T21:43:19.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001012975-26-000621","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1666307/000101297526000621/form4.xml","form_type":"4"}},{"id":715212,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32121,"kind":"organization","name":"ARCH Venture Fund IX, L.P.","position":1,"cik":"0001666306","reported_name":"ARCH Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32122,"kind":"organization","name":"ARCH Venture Fund IX Overage, L.P.","position":2,"cik":"0001666307","reported_name":"ARCH Venture Fund IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":3,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32124,"kind":"organization","name":"ARCH Venture Partners IX, L.P.","position":4,"cik":"0001723173","reported_name":"ARCH Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32125,"kind":"organization","name":"ARCH Venture Partners IX Overage, L.P.","position":5,"cik":"0001723172","reported_name":"ARCH Venture Partners IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":6,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32127,"kind":"organization","name":"ARCH Venture Partners IX, LLC","position":7,"cik":"0001723174","reported_name":"ARCH Venture Partners IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":8,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:43:19.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":2.49,"value":39840.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-26-000621","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1666307/000101297526000621/form4.xml","form_type":"4"}},{"id":715211,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32121,"kind":"organization","name":"ARCH Venture Fund IX, L.P.","position":1,"cik":"0001666306","reported_name":"ARCH Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32122,"kind":"organization","name":"ARCH Venture Fund IX Overage, L.P.","position":2,"cik":"0001666307","reported_name":"ARCH Venture Fund IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":3,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32124,"kind":"organization","name":"ARCH Venture Partners IX, L.P.","position":4,"cik":"0001723173","reported_name":"ARCH Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32125,"kind":"organization","name":"ARCH Venture Partners IX Overage, L.P.","position":5,"cik":"0001723172","reported_name":"ARCH Venture Partners IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":6,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32127,"kind":"organization","name":"ARCH Venture Partners IX, LLC","position":7,"cik":"0001723174","reported_name":"ARCH Venture Partners IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":8,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:43:19.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":1.03,"value":16480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001012975-26-000621","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1666307/000101297526000621/form4.xml","form_type":"4"}},{"id":718766,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T23:45:48.000Z","date":"2026-07-02","kind":"purchase","planned":false,"acquired":true,"shares":9821,"price":2.49,"value":24454.29,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 605,296 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2641308,"source":{"system":"sec-edgar","filing":"0001178579-26-000009","document":"form4-07022026_110743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000009/form4-07022026_110743.xml","form_type":"4"}},{"id":718765,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T23:45:48.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":71612,"price":2.49,"value":178313.88,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 605,296 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2631487,"source":{"system":"sec-edgar","filing":"0001178579-26-000009","document":"form4-07022026_110743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000009/form4-07022026_110743.xml","form_type":"4"}},{"id":718764,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T23:45:48.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":2.5,"value":250.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were all purchased at $2.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 605,296 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2559875,"source":{"system":"sec-edgar","filing":"0001178579-26-000009","document":"form4-07022026_110743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000009/form4-07022026_110743.xml","form_type":"4"}},{"id":718763,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T23:45:48.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":25930,"price":2.54,"value":65862.2,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 605,296 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2559775,"source":{"system":"sec-edgar","filing":"0001178579-26-000009","document":"form4-07022026_110743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000009/form4-07022026_110743.xml","form_type":"4"}},{"id":724441,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-29","kind":"purchase","planned":false,"acquired":true,"shares":777,"price":2.48,"value":1926.96,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2533845,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":724440,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-29","kind":"purchase","planned":false,"acquired":true,"shares":63985,"price":2.47,"value":158042.95,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.59."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2533068,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":724439,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":134,"price":2.54,"value":340.36,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.58."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2469083,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":724438,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":75047,"price":2.55,"value":191369.85,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2468949,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":724437,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":510,"price":2.56,"value":1305.6,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $2.53 to $2.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2393902,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":724436,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:56:02.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":145880,"price":2.48,"value":361782.4,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.56. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 580,669 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."}],"balance_after":2393392,"source":{"system":"sec-edgar","filing":"0001178579-26-000008","document":"form4-06292026_110657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000008/form4-06292026_110657.xml","form_type":"4"}},{"id":737344,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38012,"kind":"person","name":"Whiting Nancy","position":1,"cik":"0001880609","reported_name":"Whiting Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T23:40:59.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":1.4,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001193125-26-271474","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526271474/ownership.xml","form_type":"4"}},{"id":737635,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38112,"kind":"person","name":"Lim Jonathan E","position":1,"cik":"0001283290","reported_name":"Lim Jonathan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T23:36:07.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":48000,"derivative":{"exercise_price":1.4,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001193125-26-271465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283290/000119312526271465/ownership.xml","form_type":"4"}},{"id":738050,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38240,"kind":"person","name":"Christensen James","position":1,"cik":"0002016409","reported_name":"Christensen James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T23:31:40.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":1.4,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001193125-26-271457","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016409/000119312526271457/ownership.xml","form_type":"4"}},{"id":737736,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38158,"kind":"person","name":"Lew Jennifer","position":1,"cik":"0001465994","reported_name":"Lew Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T23:28:54.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":1.4,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001193125-26-271453","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465994/000119312526271453/ownership.xml","form_type":"4"}},{"id":930961,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68772,"kind":"person","name":"Doebele Robert","position":1,"cik":"0001856681","reported_name":"Doebele Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T12:00:06.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":230000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001193125-26-021656","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526021656/ownership.xml","form_type":"4"}},{"id":931159,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T12:00:04.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":600000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001193125-26-021655","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000119312526021655/ownership.xml","form_type":"4"}},{"id":930966,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T07:00:09.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":220000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001193125-26-021658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000119312526021658/ownership.xml","form_type":"4"}},{"id":930968,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T07:00:07.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":230000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001193125-26-021657","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000119312526021657/ownership.xml","form_type":"4"}},{"id":931081,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68789,"kind":"person","name":"HINKLE DAVID A","position":1,"cik":"0001186911","reported_name":"HINKLE DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T07:00:03.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":140000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001193125-26-021654","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186911/000119312526021654/ownership.xml","form_type":"4"}},{"id":1104044,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38240,"kind":"person","name":"Christensen James","position":1,"cik":"0002016409","reported_name":"Christensen James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:16:53.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016409/000095017025089085/ownership.xml","form_type":"4"}},{"id":1103691,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38158,"kind":"person","name":"Lew Jennifer","position":1,"cik":"0001465994","reported_name":"Lew Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:15:17.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1465994/000095017025089082/ownership.xml","form_type":"4"}},{"id":1103592,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38112,"kind":"person","name":"Lim Jonathan E","position":1,"cik":"0001283290","reported_name":"Lim Jonathan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:13:59.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000950170-25-089077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283290/000095017025089077/ownership.xml","form_type":"4"}},{"id":1103490,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:11:29.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017025089072/ownership.xml","form_type":"4"}},{"id":1103417,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":38012,"kind":"person","name":"Whiting Nancy","position":1,"cik":"0001880609","reported_name":"Whiting Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:09:35.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089067","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025089067/ownership.xml","form_type":"4"}},{"id":1104045,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78225,"kind":"person","name":"Brennan Christine","position":1,"cik":"0002016488","reported_name":"Brennan Christine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T17:21:20.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016488/000095017025089089/ownership.xml","form_type":"4"}},{"id":1287003,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68772,"kind":"person","name":"Doebele Robert","position":1,"cik":"0001856681","reported_name":"Doebele Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2025-02-03T23:38:53.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest over a period of four years, with 25% of the shares subject to the option vesting on February 3, 2026, and the remaining shares subject to the option vesting in 36 equal monthly installments thereafter, subject to continued employment or service to the issuer on each such vesting date."}],"balance_after":180000,"derivative":{"exercise_price":2.23,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000950170-25-012568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025012568/ownership.xml","form_type":"4"}},{"id":1296343,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2025-01-23T21:05:09.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":295000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":295000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":295000},"source":{"system":"sec-edgar","filing":"0000950170-25-008318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017025008318/ownership.xml","form_type":"4"}},{"id":1296260,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68789,"kind":"person","name":"HINKLE DAVID A","position":1,"cik":"0001186911","reported_name":"HINKLE DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-01-23T16:05:12.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":65000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-008320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1186911/000095017025008320/ownership.xml","form_type":"4"}},{"id":1296139,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2025-01-23T16:05:10.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":95000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000950170-25-008319","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017025008319/ownership.xml","form_type":"4"}},{"id":1296138,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-01-23T16:05:07.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":90000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-25-008317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017025008317/ownership.xml","form_type":"4"}},{"id":1427604,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":162343,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":162343,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":162343},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427603,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":257207,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":257207,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":257207},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427602,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":471282,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":471282,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":471282},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427601,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":256410,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":256410,"derivative":{"exercise_price":3.56,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":256410},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427600,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":162343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":162343},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427599,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":257207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":257207},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427598,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":471282,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":471282},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427597,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68798,"kind":"person","name":"Hornby Zachary","position":1,"cik":"0001602227","reported_name":"Hornby Zachary","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-08-20T23:10:39.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":256410,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":256410},"source":{"system":"sec-edgar","filing":"0000950170-24-099306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1602227/000095017024099306/ownership.xml","form_type":"4"}},{"id":1427220,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":48703,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":48703,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":48703},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427219,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":76173,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":76173,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":76173},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427218,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":94871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427217,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":62820,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":62820,"derivative":{"exercise_price":3.56,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":62820},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427216,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":10256,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":10256,"derivative":{"exercise_price":3.56,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":10256},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427215,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":48703},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427214,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":76173},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427213,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427212,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62820,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":62820},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427211,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10256,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":3.71,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":10256},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427194,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":16234,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":16234,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427193,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":26090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":26090,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":26090},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427192,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":35897,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024."}],"balance_after":35897,"derivative":{"exercise_price":3.56,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":35897},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427191,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":42051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":42051,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":42051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427190,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":10200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":10200,"derivative":{"exercise_price":3.56,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427189,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":29148,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":29148,"derivative":{"exercise_price":3.56,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":29148},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427188,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":32051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":32051,"derivative":{"exercise_price":3.56,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":32051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427187,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":16234},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427186,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":26090},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427185,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35897,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.49,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":35897},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427184,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":42051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427183,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427182,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29148,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":29148},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427181,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68774,"kind":"person","name":"Oien Jessica","position":1,"cik":"0001760712","reported_name":"Oien Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:00.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":32051},"source":{"system":"sec-edgar","filing":"0000950170-24-099307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760712/000095017024099307/ownership.xml","form_type":"4"}},{"id":1427283,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":23191,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":23191,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":23191},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427282,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":36852,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":36852,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":36852},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427281,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":54871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":54871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":54871},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427280,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":19948,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":19948,"derivative":{"exercise_price":3.56,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":19948},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427279,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":82051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 9, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":82051,"derivative":{"exercise_price":3.56,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":82051},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427278,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23191,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":23191},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427277,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36852,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":36852},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427276,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":54871},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427275,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19948,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":19948},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427274,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 9, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":82051},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427180,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":41745,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":41745,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":41745},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427179,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":68080,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":68080,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":68080},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427178,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":94871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427177,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":9635,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":9635,"derivative":{"exercise_price":3.56,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":9635},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427176,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":102564,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":102564,"derivative":{"exercise_price":3.56,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":102564},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427175,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41745,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":41745},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427174,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68080,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":68080},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427173,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427172,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":9635},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}}],"next_cursor":"2024-08-20T19:06:01.000000Z,1427172"}